ICARE Genetics Case Conference: Update on Contralateral Breast Cancer Risks (July 2026)

ICARE Genetics Case Conference: Update on Contralateral Breast Cancer Risks (July 2026)

by Inherited Cancer Registry (ICARE)

Life & Natural Systems Medicine & Health MFPre-clinical medicine: basic sciencesMFNMedical genetics
🎙 Inherited Cancer Registry (ICARE) 👥 991 📅 July 10, 2026 ⏱ 61 min 👁 147 📄 expert opinion 🧭 2026-08-13
Available in: English (current) Français

Keywords

contralateral breast cancerhereditary cancergenetic testingrisk managementPALB2

Summary

The video is a recording of the July 2026 ICARE Genetics Case Conference, featuring Dr. Siddhartha Yadav from the Mayo Clinic. The session begins with a welcome and housekeeping slides from the ICARE team, followed by a case presentation of a 44-year-old woman with stage 1 triple-negative breast cancer and a PALB2 pathogenic variant. The case highlights the challenge of estimating contralateral breast cancer risk, with the CANRISK tool suggesting a lifetime risk over 50%, which the expert considers overly high due to limited long-term follow-up data. Dr. Yadav then delivers a talk on contralateral breast cancer risk in hereditary breast cancer, reviewing historical data from the 2017 JAMA study on BRCA1/2, the CARRIERS study (2021), and the BRIDGES study. He presents combined data from CARRIERS and BRIDGES, showing 10-year risks for contralateral breast cancer: approximately 10% for BRCA1, 7-8% for BRCA2, 8% for PALB2 and CHEK2, and no increased risk for ATM. He emphasizes the importance of considering factors like ER status, menopausal status, and family history, and discusses the potential of polygenic risk scores. The talk concludes with a discussion of clinical implications, including the role of risk-reducing mastectomy and salpingo-oophorectomy, and a Q&A session. The video ends with a preview of upcoming case conferences.

207 words

Critical Evaluation

Value of the Information & Strength of the Argument

The video provides valuable, up-to-date information on contralateral breast cancer risk in hereditary breast cancer, synthesizing data from major studies. The argumentation is solid, with Dr. Yadav clearly explaining the limitations of current risk estimates, particularly the lack of long-term follow-up data. He effectively uses data from the CARRIERS and BRIDGES studies to support his points, and he addresses the clinical relevance of the findings. The case presentation adds a practical dimension, illustrating how risk estimates are applied in real-world scenarios. The discussion is nuanced, acknowledging the complexity of risk assessment and the need for personalized approaches.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with references to landmark studies (e.g., JAMA 2017, CARRIERS, BRIDGES) and a clear presentation of data. The sources are credible and well-known in the field. The title accurately reflects the content, which is a focused update on contralateral breast cancer risks. The video is a professional conference recording, with clear structure and expert commentary. The adéquation between title and content is excellent.

179 words

Title / Content Match

The title accurately reflects the content, which focuses on contralateral breast cancer risks in hereditary breast cancer, with a case presentation and expert discussion.

Quality & Reliability

8/10

The presentation is led by a recognized expert (Dr. Siddhartha Yadav) and references large-scale studies (CARRIERS, BRIDGES) with peer-reviewed publications. The content is clinically relevant and evidence-based, though some risk estimates are based on limited long-term follow-up data.

Chapters

Cited Sources

  • ICARE on Bluesky — Mentioned in the video description as a social media platform to follow ICARE.
  • ICARE on LinkedIn — Mentioned in the video description as a social media platform to follow ICARE.

Concurring Sources

  • CARRIERS study (2021) — Cited by Dr. Yadav as a major source for contralateral breast cancer risk estimates.
  • BRIDGES study (2021) — Cited as a UK-based study with similar findings to CARRIERS.

Contribution & Novelties

The video provides an expert update on contralateral breast cancer risk in hereditary breast cancer, synthesizing recent data from large studies (CARRIERS, BRIDGES) and highlighting the importance of personalized risk assessment. It offers practical insights for clinicians managing patients with PALB2, BRCA1/2, CHEK2, and ATM mutations.

Pour aller plus loin :

  • CARRIERS study — Key study on breast cancer risk in carriers of pathogenic variants in cancer predisposition genes.
  • BRIDGES study — Large case-control study on breast cancer risk in BRCA1/2 and other genes.
  • PredictCBC tool — Online tool for contralateral breast cancer risk prediction in BRCA1/2 and CHEK2 carriers.

100 words

Radar Profile

The radar profile shows high scores in information quantity, quality, and reliability, with a slightly lower technical level, reflecting the clinical focus and expert presentation style.

Reliability 8/10